Artificial Intelligence in Drug Optimization & Repurposing Market size (2023 - 2030)

Global Artificial Intelligence in Drug Optimization & Repurposing Market is estimated to be worth USD 450.33 Million in 2022 and is projected to reach a value of USD 7,874.43 Million by 2030, growing at a CAGR of 43% during the forecast period 2023-2030.

The Drug Discovery Process consists of several phases and sets of actions. Early Drug Discovery, Pre-Clinical Phase, Clinical Phases, and Regulatory Approval are the four major phases. The fundamental purpose of the lead optimisation phase, as the final stage in the preclinical drug development process, is to preserve the desirable qualities of the drug's key components while decreasing any inadequacies in its structure. The process of discovering new therapeutic uses for old/existing/available medications is known as drug repurposing (DR). It is a successful technique for identifying or creating novel pharmacological or therapeutic indications for medicinal compounds. AI technology is applied at every stage of the medication discovery process, which eliminates the health risks associated with preclinical studies while also significantly lowering the cost. Researchers may use AI to simplify the medication delivery process, thereby saving time and improving the efficacy and safety of pharmacological therapy. This can lead to more focused and successful medicines that are personalised to individual patients' genetic, metabolic, and clinical profiles. Based on massive pharmaceutical data and the machine learning process, AI is an excellent data mining tool. Artificial intelligence technologies combined with process performance and capability measurements may be used to proactively monitor manufacturing processes for trends. AI techniques combined with big data are projected to significantly increase the efficacy of medication repurposing and the discovery of novel treatments for a variety of complicated human diseases such as COVID-19, malignancies, Alzheimer's disease, and others.

Global Artificial Intelligence in Drug Optimization & Repurposing Market Drivers:

Increasing Adoption has significantly boosted the growth of AI.

Data science and artificial intelligence (AI) are becoming increasingly crucial in medication research and development. In addition to developing novel treatments, AI accelerates the work of current drug development and clinical teams, allowing them to make more informed and precise research decisions. In small-molecule drug development, AI may add value in four ways: access to new biology, enhanced or novel chemistry, higher success rates, and faster and cheaper discovery methods. Furthermore, Artificial intelligence can assist researchers in analysing enormous datasets and identifying patterns that would be difficult or impossible to find using traditional approaches. This can lead to more effective therapies. A lot of R&D activities are being provided to develop computational tools to further understand the diseases and develop effective drugs against the same.

The surge in the number of cases of chronic disease has delved into the prospects of AI.

According to WHO, if the current trend continues, chronic diseases such as cardiovascular disease, cancer, diabetes, and respiratory illnesses will account for 86% of the 90 million deaths each year by 2050, representing a staggering 90% increase in absolute numbers since 2019. AI can swiftly grasp how cancer cells gain resistance to anticancer treatments, which can aid in drug development and therapeutic use. AI increases tumour neoantigen detection and tumour immunotherapy effectiveness. Based on clinical data, chest imaging, lung pathology, and pulmonary function tests, AI can assist in establishing diagnosis and predicting outcomes in pulmonary disorders. AI platforms provide valuable insights for drug discovery and minimizing the severity of diseases. Therefore, these factors are projected to enhance and discover more knowledge thereby having a lot of scope in the coming period.

Global Artificial Intelligence in Drug Optimization & Repurposing Market Challenges:

The advanced tools used and being developed require substantial amounts of investments which can be the biggest hindrance in the healthcare industry. To produce accurate predictions and choices, AI systems rely on high-quality data. However, data used in medication development is frequently insufficient, inconsistent, or biased. This can result in erroneous or unreliable AI algorithm outputs, which might stymie the medication development process. Furthermore, during clinical trials, only a few molecules can be successful in providing accurate data which can bleed the sector dry.

Global Artificial Intelligence in Drug Optimization & Repurposing Market Opportunities:

Opportunities are being provided in the R&D sector through collaborations, investments, and schemes. The research field has enormous amounts of publications, journals, and books for a better understanding which combines the areas of computer science, machine learning and an understanding of drug development. A lot of pharmaceutical and IT companies are working to further explore the understanding by employing bioinformatics tools to get a better understanding of the abnormalities present in the sequences. All these initiatives have caused a remarkable change helping in generating an exponential curve in the industry.

COVID-19 Impact on the Global Artificial Intelligence in Drug Optimization & Repurposing Market:

Despite the economic slowdown during the pandemic, the AI field turned out to be beneficial. Skilled professionals and Research Scientists were hired to detect patterns and for vaccine development. One of the objectives and responsibilities of AI in vaccine development was to study the proteins that comprised the virus, such as the spike protein(s). An AI system could sift through hundreds of components in a complex structure to select the ones that were most likely to evoke a significant immune response. With the increased use of AI in the healthcare industry, it was possible to anticipate early COVID-19 signs and thereby restrict the spread of the virus. It was used to screen and follow patients, as well as anticipate future illnesses, by employing algorithms that analyse data to uncover meaningful trends.

Global Artificial Intelligence in Drug Optimization & Repurposing Market Recent Developments:

• In May 2023, Google Cloud launched two A.I.-powered tools to accelerate drug discovery and precision medicine. Target and Lead Identification Suite, is designed to help companies predict and understand the structure of proteins, a fundamental part of drug development. Multiomics Suite will help researchers ingest, store, analyse and share mass amounts of genomic data. 

• In July 2021, an AI system by DeepMind called AlphaFold predicted the protein structures for 330,000 proteins, including all 20,000 proteins in the human genome.

• In January 2021, BenevolentAI announced that AstraZeneca had selected the first AI-generated drug target from their 2019 collaboration – a novel chronic kidney disease (CKD) target. 

• During the second half of 2020, Pfizer, invested $120 million in biotechnology innovation through the Pfizer Breakthrough Growth Initiative and effectively used AI to conduct COVID-19 vaccine and streamline distribution. The company drew on digital technologies and AI to roll out its vaccine to market in less than a year.

• Exscientia revealed the first-ever AI-designed medicinal molecule to start human clinical trials in early 2020.

ARTIFICIAL INTELLIGENCE IN DRUG OPTIMIZATION & REPURPOSING MARKET REPORT COVERAGE:

Global Artificial Intelligence in Drug Optimization & Repurposing Market Segmentation: By Therapeutic Area

• Oncology

• Neurodegenerative Diseases

• Cardiovascular Disease

• Genetic Diseases

• Metabolic Diseases

• Infectious Disease

• Others

Oncology is the largest growing in the Global Artificial Intelligence in Drug Optimization & Repurposing Market. This is because many malignancies are predicted and automated using artificial intelligence (AI), which has emerged as a viable tool for enhancing healthcare accuracy and patient outcomes. Deep knowledge-based AI applications in cancer include risk assessment, early diagnosis, patient prognosis estimate, and therapy selection thereby increasing life expectancy. The infectious disease segment is the fastest growing owing to factors like helping with early detection, optimising pharmaceutical and non-pharmaceutical therapeutic tactics, prediction models, understanding infection mechanisms, telemedicine, vaccine development, etc.

Global Artificial Intelligence in Drug Optimization & Repurposing Market Segmentation: By Technology

• Machine Learning

• Deep Learning

  • Support Vector Machine (SVM)

  • DeepPurpose 20

• Natural Language Processing

• Virtual Screening

• Others

Machine Learning is the largest growing in the Global Artificial Intelligence in Drug Optimization & Repurposing Market. Machine learning approaches enhance decision-making in pharmaceutical data across a wide range of applications, including QSAR analysis, hit discovery, and de novo drug designs, to produce more accurate results. Deep Learning, a subset of Machine Learning is the fastest-growing segment in the Global Artificial Intelligence in Drug Optimization & Repurposing Market. SVM is widely used for drug optimization. The capacity of SVMs to categorise active or inactive molecules has allowed substances to be prioritised for virtual screening. DeepPurpose [20] is majorly used for drug repurposing because it helps in drug–target interaction (DTI) integrating encoding-based approaches of drug molecules and protein amino acid sequences.

Global Artificial Intelligence in Drug Optimization & Repurposing Market Segmentation: By Offering

• Services

• Softwares

The service sector is the largest growing in the Global Artificial Intelligence in Drug Optimization & Repurposing Market owing to the demand, time taken, and accuracy associated with the same. The service sector is the fastest-growing sector in the coming years.

Global Artificial Intelligence in Drug Optimization & Repurposing Market Segmentation: By End-Users

• Biotechnology firms and Pharmaceutical Companies

• Research Organizations

• Academic Institutes

• Others

Biotechnology firms and Pharmaceutical Companies are the largest growing in the Global Artificial Intelligence in Drug Optimization & Repurposing Market. This is mainly because of better funding, opportunities, collaborations, advanced technologies and databases. However, research organizations are the fastest growing because of schemes, initiatives and grants being provided by Government bodies.

Global Artificial Intelligence in Drug Optimization & Repurposing Market Segmentation: By Region

• North America

• Europe

• Asia-Pacific

• South America

• Middle East & Africa

North America dominates the Global Artificial Intelligence in Drug Optimization & Repurposing Market owing to huge investments, economy, advanced research, increasing adoption, collaborations and partnerships. USA and Canada are the top leading countries. Asia Pacific is the fastest growing because of changes in regulations, grants, funding, and research activities regarding the concept of personalised medicine. China is a Tier 1 country with the most AI centres and is undergoing national digitization in the healthcare industry.

Global Artificial Intelligence in Drug Optimization & Repurposing Market Key Players:

1. Microsoft

2. IBM

3. Exscientia

4. GNS Healthcare

5. Alphabet

6. Benevolent AI

7. Cloud Pharmaceuticals

8. NVIDIA Corporation

9. DEEP GENOMICS

10. Cyclica